Persistent generalized lymphadenopathy: Clinical characteristics of a lymphadenopathy syndrome in intravenous drug abusers

U. Tirelli, E. Vaccher, A. Carbone, R. Volpe, P. De Paoli, G. Santini, S. Monfardini

Research output: Contribution to journalArticle

Abstract

Persistent generalized lymphadenopathy (PGL) is the most frequent AIDS related manifestation in homosexual men. From May 1984 to March 1985, 45 (38%) out of 117 intravenous (iv) drug abusers evaluated had PGL. Thirty-two were males and 13 females (median age 25 years). All patients referred to the frequent sharing of syringes. The median duration of lymphadenopathy was 3 months (range 3-60) with a median number of involved extrainguinal sites of 4 (range 2-7). Systemic symptoms and anergy to skin tests were common, whereas splenomegaly and past infections were less frequently encountered. Hypergammaglobulinemia and an inverted T helper/suppressor ratio and lymphopenia were found in 78%, 43%, and 20% of the patients, respectively; the presence of HTLV-III antibodies was demonstrated in 12 (46%) of the 26 tested patients. Histologically, excised lymph nodes from 14 patients exhibited a marked follicular hyperplasia, diffuse plasmacytosis, and a conspicuous capillary proliferation. All patients are followed on a regular basis with clinical examination and laboratory tests; in no case has AIDS or a malignant lymphoma so far developed.

Original languageEnglish
Pages (from-to)227-230
Number of pages4
JournalAIDS Research
Volume2
Issue number3
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Immunology
  • Virology

Fingerprint Dive into the research topics of 'Persistent generalized lymphadenopathy: Clinical characteristics of a lymphadenopathy syndrome in intravenous drug abusers'. Together they form a unique fingerprint.

  • Cite this

    Tirelli, U., Vaccher, E., Carbone, A., Volpe, R., De Paoli, P., Santini, G., & Monfardini, S. (1986). Persistent generalized lymphadenopathy: Clinical characteristics of a lymphadenopathy syndrome in intravenous drug abusers. AIDS Research, 2(3), 227-230.